STERIS plc (NYSE: STE; Irish-domiciled holding company structure post-2018 Synergy Health merger) FY2025 (fiscal year ending March 2026) revenue ~$5.4-5.6B (+5-8%) with adj. EPS ~$8.50-10.00 reflecting continued post-2024 surgical procedure recovery + selected Healthcare segment leadership ($3.8B; ~50%+ US hospital sterilization market share) + selected April 2021 Cantel Medical $4.6B integration realization + selected ~20-year continuous dividend track + selected operational excellence under CEO Daniel Carestio (~3-year tenure since June 2022). Leading global infection prevention + sterilization products + services firm. Founded 1985 in Mentor Ohio (~40-year heritage; selected initial focus on selected sterilization technology); current STERIS plc structure formed via 2018 Synergy Health merger creating Irish-domiciled holding company. Headquartered in Dublin Ireland (operational HQ Mentor Ohio); ~17,000+ employees globally with ~$5.4-5.6B revenue. Three reporting segments: Healthcare ~70% revenue ($3.8B — surgical instrument cleaning + sterilization + infection prevention products + services for hospitals; ~50%+ US hospital sterilization market share + dominant capital equipment + sterilizers + washers + post-Cantel endoscopy reprocessing; capital equipment ~$700M+ + consumables ~$1.2B+ + service contracts ~$800M-1B + endoscopy reprocessing ~$500M+), Applied Sterilization Technologies ~20% ($1.0B — contract sterilization for medical device manufacturers + biopharma; gamma + ethylene oxide + E-beam sterilization), Life Sciences ~10% ($0.5B — sterilization for biopharma + pharmaceutical manufacturing). April 2021 Cantel Medical $4.6B all-cash + stock acquisition: transformative deal contributed ~$1.1B revenue + ~3,500 employees + medical device sterilization + endoscopy reprocessing expansion; ~$300-400M+ annualized cost synergies achieved by FY2024; selected post-2021 Cantel integration into Healthcare segment + medical device manufacturer sterilization customers expanded. CEO Daniel Carestio since June 2022 (succeeded Walt Rosebrough CEO 2007-June 2022 retired who led 2007-2022 strategic transformation including 2018 Synergy Health merger + 2021 Cantel Medical $4.6B; Carestio ex-STERIS COO 2019-2022 + ex-various STERIS roles + ~25-year career). Selected internal succession reflected board's preference for operational continuity through Cantel integration. Capital return: ~$2.20-2.40 annual dividend FY2025 (~$0.55-0.60/quarter; ~20+ consecutive year continuous increases); modest buybacks $200-400M FY2025; investment-grade Baa1/BBB+ credit ratings; FCF $700M-900M. FY2026 thesis: Healthcare cycle recovery + Cantel integration realization + AST cycle recovery + ~21-year dividend track. Risks: major Cantel goodwill impairment, hospital capex pause, medical device manufacturing cycle reversal, currency translation severe.

[STE] STERIS Thesis 2026: Cantel Integration Tests Sterilization Services Cycle

Key Takeaways

Healthcare Segment Leadership: Healthcare segment ~$3.8B FY2025 (~70% of total; +5-8% YoY); selected surgical instrument cleaning + sterilization + selected infection prevention products + services for hospitals; selected ~50%+ US hospital sterilization market share; FY2026 expected Healthcare toward $4.0-4.2B (+5-8%) on continued surgical procedure recovery + selected infection prevention demand.
April 2021 Cantel Medical $4.6B Integration: Selected April 2021 Cantel Medical $4.6B all-cash + stock acquisition (transformative; selected medical device sterilization + endoscopy reprocessing expansion); selected ~$300-400M+ annualized cost synergies achieved by FY2024; selected ~$1B+ Cantel revenue contribution within Healthcare; FY2026 catalyst: continued integration + selected medical device manufacturer sterilization growth.
Applied Sterilization Technologies Recovery: AST segment ~$1.0B FY2025 (~20% of total; +0-5% YoY); selected contract sterilization for medical device manufacturers + biopharma; selected post-2024 medical device manufacturing cycle stabilization + selected biopharma cycle recovery; FY2026 expected AST toward $1.05-1.15B (+5-10%).
20+ Year Dividend Track Record: ~~$2.20-2.40 annual dividend FY2025 (~~$0.55-0.60/quarter; ~20+ consecutive year continuous increases); modest buybacks $200-400M; investment-grade Baa1/BBB+ credit ratings; FCF $700M-900M; FY2026 expected total capital return $400-700M.

Company Background

STERIS plc (NYSE: STE; Irish-domiciled holding company structure post-2018 Synergy Health merger) is the leading global infection prevention + sterilization products + services firm. Founded 1985 in Mentor Ohio (selected ~40-year heritage; selected initial focus on selected sterilization technology); selected various rebrands and acquisitions through history; selected current STERIS plc structure formed via 2018 Synergy Health merger creating Irish-domiciled holding company. Headquartered in Dublin Ireland (operational HQ Mentor Ohio); ~17,000+ employees globally with FY2025 (fiscal year ending March 2026) revenue ~$5.4-5.6B (+5-8% YoY) generating ~$700-850M net income (~13-15% net margin) and ~$8.50-10.00 EPS on ~99M diluted shares.

The company operates three reporting segments: Healthcare ~70% of revenue ($3.8B — selected surgical instrument cleaning + sterilization + selected infection prevention products + services for hospitals; selected ~50%+ US hospital sterilization market share + selected dominant capital equipment + sterilizers + washers + selected post-Cantel endoscopy reprocessing), Applied Sterilization Technologies ~20% ($1.0B — selected contract sterilization for medical device manufacturers + biopharma; selected gamma + ethylene oxide + selected E-beam sterilization), and Life Sciences ~10% ($0.5B — selected sterilization for biopharma + selected pharmaceutical manufacturing).

CEO Daniel Carestio since June 2022 (~3-year tenure; succeeded Walt Rosebrough CEO 2007-June 2022 retired who led 2007-2022 strategic transformation including 2018 Synergy Health merger + 2021 Cantel Medical $4.6B; Carestio ex-STERIS COO 2019-2022 + ex-various STERIS roles + selected ~25-year career). Selected internal succession reflected board's preference for operational continuity through Cantel integration.

April 2021 Cantel Medical $4.6B Integration

Selected April 2021 Cantel Medical $4.6B all-cash + stock acquisition represents STERIS's largest transformative transaction. Selected key economics: (i) Cantel Medical contributed ~$1.1B revenue + ~3,500 employees + selected medical device sterilization + endoscopy reprocessing expansion; (ii) selected ~$300-400M+ annualized cost synergies achieved by FY2024; (iii) selected post-2021 Cantel integration into Healthcare segment; (iv) selected medical device manufacturer sterilization customers expanded.

FY2026 catalyst: continued Cantel integration + selected medical device manufacturer sterilization growth + selected operating margin expansion toward 22-24% adj. operating margin reflecting integration benefits.

Material change rule: Cantel cost synergies decline below $250M annualized (would signal severe integration underperformance) OR major Cantel goodwill impairment OR major endoscopy reprocessing competitive substitution.

Healthcare Segment: $3.8B Trajectory

Healthcare segment revenue ~$3.8B FY2025 (~70% of total; +5-8% YoY) reflects: (i) selected capital equipment (selected sterilizers + washers + selected ~$700M+ revenue); (ii) selected consumables + supplies (selected ~$1.2B+ recurring); (iii) selected service contracts (selected ~$800M-1B recurring); (iv) selected post-Cantel endoscopy reprocessing (selected ~$500M+); (v) selected ~50%+ US hospital sterilization market share. FY2026 expected Healthcare toward $4.0-4.2B (+5-8%).

Applied Sterilization Technologies + Life Sciences

AST segment ~$1.0B FY2025 (~~20% of total; +0-5% YoY) reflects: (i) selected contract sterilization for medical device manufacturers (~~$700-800M; selected gamma + ethylene oxide + E-beam); (ii) selected biopharma sterilization; (iii) selected post-2024 medical device manufacturing cycle stabilization. FY2026 expected AST toward $1.05-1.15B (+5-10%). Life Sciences ~$0.5B (~10%) selected sterilization for biopharma + pharmaceutical manufacturing; FY2026 expected $0.5-0.55B (+0-10%).

Key Core Metrics

Metric	FY2022	FY2023	FY2024	FY2025E	FY2026E
Total Revenue	$4.65B	$5.13B	$5.36B	$5.4-5.6B	$5.7-6.0B
Healthcare	$3.04B	$3.45B	$3.65B	$3.8B	$4.0-4.2B
AST	$1.02B	$1.0B	$1.0B	$1.0B	$1.05-1.15B
Life Sciences	$0.59B	$0.55B	$0.50B	$0.5B	$0.5-0.55B
Adj. Operating Margin	22%	21%	22%	22-23%	22-24%
Adj. EPS	$7.85	$8.32	$8.78	$8.50-10.00	$9.50-11.00
FCF	$700M	$750M	$800M	$700M-900M	$750M-1.0B

Capital Return	FY2024	FY2025E	FY2026E
Dividend per Share	$2.08	$2.20-2.40	$2.30-2.55
Dividend Continuous Years	~19	~20	~21
Buybacks	$200M	$200-400M	$300-500M
Total Capital Return	$400M	$420-640M	$530-755M
Credit Rating	Baa1/BBB+	Baa1/BBB+	Baa1/BBB+

Market Evaluation

STE currently trades at ~22-26x earnings reflecting: (i) selected category-leading hospital sterilization franchise; (ii) selected ~20-year continuous dividend track record; (iii) selected Cantel Medical post-2021 integration optionality; (iv) selected post-2024 surgical procedure recovery cycle; offset by (v) selected post-Cantel deleveraging; (vi) selected hospital capex cycle dependency.

Selected peer comparison: Stryker (SYK ~25-28x P/E orthopedics + medical), Becton Dickinson (BDX ~17-20x P/E medical device + life sciences), Baxter (BAX ~12-15x P/E medical device + renal), Hologic (HOLX ~15-18x P/E women's health). STE valuation reflects category-leading sterilization positioning premium.

FY2026 catalysts: (i) Healthcare cycle recovery; (ii) Cantel integration realization; (iii) ~21-year dividend track; (iv) AST cycle recovery. Risks: (i) major Cantel goodwill impairment; (ii) hospital capex pause; (iii) medical device manufacturing cycle reversal; (iv) currency translation severe.

Cantel Integration and Sterilization Services Cycle

The FY2026 thesis hinges on STERIS's ability to sustain Healthcare segment leadership + complete Cantel Medical integration + capitalize on AST cycle recovery. Healthcare trajectory toward $4.0-4.2B FY2026 (+5-8%) signals selected continued surgical procedure recovery + selected hospital capex stabilization + selected Cantel cross-sell.

AST recovery toward $1.05-1.15B FY2026 (+5-10%) reflects medical device manufacturing cycle stabilization. Total revenue $5.7-6.0B FY2026 (+5-8%) + adj. EPS $9.50-11.00 (+10-15%) reflects selected operational leverage + Cantel integration benefits.

Material risks: (i) Cantel goodwill impairment; (ii) hospital capex pause severe; (iii) AST competitive substitution from Sotera Health + selected; (iv) currency translation severe.

FY2026-2027 base case: revenue $5.7-6.0B (+5-8%) + $6.0-6.4B (+5-7%); adj. EPS $9.50-11.00 + $10.50-12.50 (+10-15% growth); dividend $2.30-2.55 + $2.45-2.75 maintaining 21-22 consecutive year dividend track; capital return $530-755M + $600-850M. Selected category-leading sterilization franchise + selected Cantel integration optionality + selected dividend continuity support continued compounding through FY2027.